abstract: Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer

Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.


Abstract

OBJECTIVE: 
To identify factors that increase the risk of neutropenic events in women with advanced ovarian carcinoma receiving initial chemotherapy.

METHODS: 
Multi-center retrospective study of women with FIGO stage III-IV epithelial ovarian cancer treated postoperatively with multi-agent intravenous chemotherapy 1995-2008.......

CONCLUSION:
While SN is fairly common, FN occurs infrequently in women with EOC undergoing taxane and platin-based chemotherapy and primary prophylactic growth factor support is not indicated. However, women older than 60 years of age receiving non-carboplatin containing regimens are at higher risk for FN and warrant closer surveillance.

The Oncologist: commentary + link to original paper - Calcium and Magnesium Prophylaxis for Oxaliplatin-Related (taxanes) Neurotoxicity: Is It a Trade-off Between Drug Efficacy and Toxicity?

 1)  link to commentary: 

 Calcium and Magnesium Prophylaxis for Oxaliplatin-Related Neurotoxicity: Is It a Trade-off Between Drug Efficacy and Toxicity?

"In this context, a large international academic trial involving several U.S. and European oncological centers—the Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization (CI-PERINOMS) study[16]—recently completed the enrollment of >280 patients with CIPN who were examined with an extended series of scales and questionnaires to assess their reliability and validity, a critical step in the search for the optimal method to detect and describe its features in daily practice and in clinical trials. In fact, until reliable, valid, reproducible, and responsive methods are used to properly assess CIPN, any effort to establish an effective neuroprotection treatment will be unrealistic."

2)  link to original paper:

Calcium and Magnesium Prophylaxis for Oxaliplatin-Related Neurotoxicity: Is It a Trade-off Between Drug Efficacy and Toxicity?

"......Furthermore, there is a lack of standardization in timing of assessment of neurotoxicity and inadequate assessment of long-term neurotoxicity related to oxaliplatin between studies investigating Ca/Mg prophylaxis. Also, because of the initial concerns raised by the IDMC examining the CONCePT trial, many of the major trials were terminated early and are thus underpowered. The NCCTG has initiated another prospective randomized, double-blinded trial aimed at addressing these issues."  (safety)